Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease

Arthritis Research and Therapy

Volumn 10, Issue 1, 2008, Pages

  Zenz, Rainer ^a,b   Eferl, Robert ^a,b   Scheinecker, Clemens ^b   Redlich, Kurt ^b   Smolen, Josef ^b   Schonthaler, Helia B ^c   Kenner, Lukas ^a,b   Tschachler, Erwin ^d   Wagner, Erwin F ^c,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d Universitatsklinik fur Dermatologie   (Austria)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; TUMOR NECROSIS FACTOR ALPHA; PROTEIN C FOS; PROTEIN C JUN;

ALLERGIC ASTHMA; ARTHROPATHY; BONE DEVELOPMENT; BONE DISEASE; CARCINOGENESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; ENTERITIS; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN DISEASE; ANIMAL; EPIDERMIS; INFLAMMATION; METABOLISM;

ANIMALS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BONE DISEASES; CYTOKINES; EPIDERMIS; HUMANS; INFLAMMATION; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PSORIASIS; SKIN DISEASES; TRANSCRIPTION FACTOR AP-1;

EID: 47049129276     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2338     Document Type: Review

References (51)

1. Zenz R Wagner EF Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors Int J Biochem Cell Biol 2006, 38:1043-1049. 10.1016/j.biocel.2005.11.011 16423552
2. Wagner EF Eferl R Fos/AP-1 proteins in bone and the immune system Immunol Rev 2005, 208:126-140. 10.1111/j.0105-2896.2005.00332.x 16313345
3. Shaulian E Karin M AP-1 as a regulator of cell life and death Nat Cell Biol 2002, 4:E131-E136. 10.1038/ncb0502-e131 11988758
4. Chang L Karin M Mammalian MAP kinase signalling cascades Nature 2001, 410:37-40. 10.1038/35065000 11242034
5. Riera-Sans L Behrens A Regulation of alphabeta/gammadelta T cell development by the activator protein 1 transcription factor c-Jun J Immunol 2007, 178:5690-5700. 17442952
6. Schorpp-Kistner M Wang ZQ Angel P Wagner EF JunB is essential for mammalian placentation EMBO J 1999, 18:934-948. 1171186 10022836 10.1093/ emboj/18.4.934
7. Thepot D Weitzman JB Barra J Segretain D Stinnakre MG Babinet C Yaniv M Targeted disruption of the murine junD gene results in multiple defects in male reproductive function Development 2000, 127:143-153. 10654608
8. Stepniak E Ricci R Eferl R Sumara G Sumara I Rath M Hui L Wagner EF c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity Genes Dev 2006, 20:2306-2314. 1553212 16912279 10.1101/ gad.390506
9. Passegue E Wagner EF JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression EMBO J 2000, 19:2969-2979. 203376 10856241 10.1093/emboj/19.12.2969
10. Weitzman JB Fiette L Matsuo K Yaniv M JunD protects cells from p53-dependent senescence and apoptosis Mol Cell 2000, 6:1109-1119. 10.1016/S1097-2765(00)00109-X 11106750
11. Jochum W David JP Elliott C Wutz A Plenk H Jr Matsuo K Wagner EF Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 Nat Med 2000, 6:980-984. 10.1038/79676 10973316
12. Sabatakos G Sims NA Chen J Aoki K Kelz MB Amling M Bouali Y Mukhopadhyay K Ford K Nestler EJ Baron R Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis Nat Med 2000, 6:985-990. 10.1038/79683 10973317
13. Eferl R Hoebertz A Schilling AF Rath M Karreth F Kenner L Amling M Wagner EF The Fos-related antigen Fra-1 is an activator of bone matrix formation EMBO J 2004, 23:2789-2799. 514946 15229648 10.1038/ sj.emboj.7600282
14. McHenry JZ Leon A Matthaei KI Cohen DR Overexpression of fra-2 in transgenic mice perturbs normal eye development Oncogene 1998, 17:1131-1140. 10.1038/sj.onc.1202044 9764823
15. Karreth F Hoebertz A Scheuch H Eferl R Wagner EF The AP1 transcription factor Fra2 is required for efficient cartilage development Development 2004, 131:5717-5725. 10.1242/dev.01414 15509771
16. Eferl R Zenz R Theussl HC Wagner EF Simultaneous generation of fra-2 conditional and fra-2 knock-out mice Genesis 2007, 45:447-451. 10.1002/ dvg.20311 17607691
17. Kenner L Hoebertz A Beil T Keon N Karreth F Eferl R Scheuch H Szremska A Amling M Schorpp-Kistner M Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects J Cell Biol 2004, 164:613-623. 10.1083/jcb.200308155 14769860 2171977
18. Karin M Inflammation-activated protein kinases as targets for drug development Proc Am Thorac Soc 2005, 2:386-390. discussion 394-395 10.1513/pats.200504-034SR 16267367
19. Kawai T Sato S Ishii KJ Coban C Hemmi H Yamamoto M Terai K Matsuda M Inoue J Uematsu S et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6 Nat Immunol 2004, 5:1061-1068. 10.1038/ni1118 15361868
20. Rincon M Derijard B Chow CW Davis RJ Flavell RA Reprogramming the signalling requirement for AP-1 (activator protein-1) activation during differentiation of precursor CD4+T-cells into effector Th1 and Th2 cells Genes Funct 1997, 1:51-68. 9680328
21. Hartenstein B Teurich S Hess J Schenkel J Schorpp-Kistner M Angel P Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB EMBO J 2002, 21:6321-6329. 136952 12456639 10.1093/emboj/cdf648
22. Gao M Labuda T Xia Y Gallagher E Fang D Liu YC Karin M Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch Science 2004, 306:271-275. 10.1126/science.1099414 15358865
23. Meixner A Karreth F Kenner L Wagner EF JunD regulates lymphocyte proliferation and T helper cell cytokine expression EMBO J 2004, 23:1325-1335. 381408 15029240 10.1038/sj.emboj.7600133
24. Reichardt HM Kaestner KH Tuckermann J Kretz O Wessely O Bock R Gass P Schmid W Herrlich P Angel P Schutz G DNA binding of the glucocorticoid receptor is not essential for survival Cell 1998, 93:531-541. 10.1016/ S0092-8674(00)81183-6 9604929
25. Smolen JS Hayer S Schett G Redlich K Aringer M Kollias G Wagner E Steiner G Autoimmunity and rheumatoid arthritis [abstract] Autoimmun Rev 2004, 3(Suppl 1):S23. 15309784
26. Goronzy JJ Weyand CM T-cell regulation in rheumatoid arthritis Curr Opin Rheumatol 2004, 16:212-217. 10.1097/00002281-200405000-00008 15103247
27. Firestein GS Evolving concepts of rheumatoid arthritis Nature 2003, 423:356-361. 10.1038/nature01661 12748655
28. Kong YY Feige U Sarosi I Bolon B Tafuri A Morony S Capparelli C Li J Elliott R McCabe S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 1999, 402:304-309. 10.1038/46303 10580503
29. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X 9568710
30. O'Gradaigh D Compston JE T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion Rheumatology (Oxford) 2004, 43:122-130. 10.1093/rheumatology/keg447 12867576
31. Yasuda H Shima N Nakagawa N Mochizuki SI Yano K Fujise N Sato Y Goto M Yamaguchi K Kuriyama M et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 1998, 139:1329-1337. 10.1210/en.139.3.1329 9492069
32. Wada T Nakashima T Hiroshi N Penninger JM RANKL-RANK signaling in osteoclastogenesis and bone disease Trends Mol Med 2006, 12:17-25. 10.1016/j.molmed.2005.11.007 16356770
33. Matsuo K Galson DL Zhao C Peng L Laplace C Wang KZ Bachler MA Amano H Aburatani H Ishikawa H Wagner EF Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos J Biol Chem 2004, 279:26475-26480. 10.1074/jbc.M313973200 15073183
34. Takayanagi H Kim S Matsuo K Suzuki H Suzuki T Sato K Yokochi T Oda H Nakamura K Ida N et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta Nature 2002, 416:744-749. 10.1038/416744a 11961557
35. Burrage PS Mix KS Brinckerhoff CE Matrix metalloproteinases: Role in arthritis Front Biosci 2006, 11:529-543. 10.2741/1817 16146751
36. Han Z Boyle DL Chang L Bennett B Karin M Yang L Manning AM Firestein GS c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis J Clin Invest 2001, 108:73-81. 209341 11435459 10.1172/JCI200112466
37. Smolen JS Aletaha D Koeller M Weisman MH Emery P New therapies for treatment of rheumatoid arthritis Lancet 2007, 370:1861-1874. 10.1016/ S0140-6736(07)60784-3 17570481
38. Zenz R Scheuch H Martin P Frank C Eferl R Kenner L Sibilia M Wagner EF c-Jun regulates eyelid closure and skin tumor development through EGFR signaling Dev Cell 2003, 4:879-889. 10.1016/S1534-5807(03)00161-8 12791272
39. Lowes MA Bowcock AM Krueger JG Pathogenesis and therapy of psoriasis Nature 2007, 445:866-873. 10.1038/nature05663 17314973
40. Mease P Psoriatic arthritis update Bull NYU Hosp Jt Dis 2006, 64:25-31. 17121486
41. Nickoloff BJ Keratinocytes regain momentum as instigators of cutaneous inflammation Trends Mol Med 2006, 12:102-106. 10.1016/ j.molmed.2006.01.001 16443394
42. Nickoloff BJ Nestle FO Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 2004, 113:1664-1675. 420513 15199399 10.1172/JCI200422147
43. Zenz R Eferl R Kenner L Florin L Hummerich L Mehic D Scheuch H Angel P Tschachler E Wagner EF Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins Nature 2005, 437:369-375. 10.1038/nature03963 16163348
44. Johansen C Kragballe K Rasmussen M Dam TN Iversen L Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin Br J Dermatol 2004, 151:600-607. 10.1111/ j.1365-2133.2004.06088.x 15377346
45. Haider AS Duculan J Whynot JA Krueger JG Increased JunB mRNA and protein expression in psoriasis vulgaris lesions J Invest Dermatol 2006, 126:912-914. 10.1038/sj.jid.5700183 16470177
46. Hobbs JA May R Tanousis K McNeill E Mathies M Gebhardt C Henderson R Robinson MJ Hogg N Myeloid cell function in MRP-14 (S100A9) null mice Mol Cell Biol 2003, 23:2564-2576. 150714 12640137 10.1128/ MCB.23.7.2564-2576.2003
47. Conrad C Nestle FO Animal models of psoriasis and psoriatic arthritis: an update Curr Rheumatol Rep 2006, 8:342-347. 10.1007/s11926-006-0063-x 16973107
48. Gudjonsson JE Johnston A Dyson M Valdimarsson H Elder JT Mouse models of psoriasis J Invest Dermatol 2007, 127:1292-1308. 10.1038/sj.jid.5700807 17429444
49. Keffer J Probert L Cazlaris H Georgopoulos S Kaslaris E Kioussis D Kollias G Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis EMBO J 1991, 10:4025-4031. 453150 1721867
50. Jo SJ Park JY Yoon HS Youn JI Case of acrodermatitis continua accompanied by psoriatic arthritis J Dermatol 2006, 33:787-791. 10.1111/ j.1346-8138.2006.00180.x 17073995
51. Serarslan G Guler H Karazincir S The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis Clin Rheumatol 2007, 26:1245-1247. 10.1007/s10067-006-0476-y 17119859